Mingxi Li is the founder of GT Apeiron Therapeutics. GT Apeiron Therapeutics has raised $18M in total funding. Latest round: Series A.
Mingxi Li is the CEO of Apeiron Therapeutics, an investor and entrepreneur specializing in identifying and commercializing early-stage life science innovations. He aims to build Apeiron into a world-class biotech company. Prior to this role, Dr. Li was a partner at GT Healthcare Capital Partners, and focused on healthcare investments at Jiuding Capital and global early-stage pharmaceutical investments at Simcere Pharmaceutical Group. He holds a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign.
Full founder directory · Investor directory · Company funding database · Fundraising library